Merck Cancidas
Executive Summary
Echinocandin cidal antifungal MK-991 has entered Phase III for fungal infections. The medication is dosed intravenously once-daily, the company said in its annual report. Carbapenem antibiotic MK-826 has also entered Phase III
You may also be interested in...
Versicor V-Echinocandin Vs. Fluconazole Phase III Planned For 2001
Versicor expects to initiate an 18-month Phase III comparative study of its antifungal V-echinocandin versus fluconazole in the first quarter of 2001.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011